AU7000798A - Pharmaceutical antigen-antibody preparation - Google Patents

Pharmaceutical antigen-antibody preparation

Info

Publication number
AU7000798A
AU7000798A AU70007/98A AU7000798A AU7000798A AU 7000798 A AU7000798 A AU 7000798A AU 70007/98 A AU70007/98 A AU 70007/98A AU 7000798 A AU7000798 A AU 7000798A AU 7000798 A AU7000798 A AU 7000798A
Authority
AU
Australia
Prior art keywords
antigen
antibody preparation
pharmaceutical
pharmaceutical antigen
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70007/98A
Inventor
Martha Eibl
Thomas Kreil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Publication of AU7000798A publication Critical patent/AU7000798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention relates to a pharmaceutical preparation comprising an antigen, specially an antigen of a pathogen, and at least one antibody, which binds the antigen or the pathogen, wherein at least one epitope of the antigen is free and immunogenic. Further disclosed is a method for the production of said pharmaceutical preparation and its use. 00000
AU70007/98A 1996-11-05 1997-11-04 Pharmaceutical antigen-antibody preparation Abandoned AU7000798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19645559 1996-11-05
DE19645559A DE19645559A1 (en) 1996-11-05 1996-11-05 Pharmaceutical antigen / antibody preparation
PCT/EP1997/006077 WO1998019703A2 (en) 1996-11-05 1997-11-04 Pharmaceutical antigen-antibody preparation

Publications (1)

Publication Number Publication Date
AU7000798A true AU7000798A (en) 1998-05-29

Family

ID=7810692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70007/98A Abandoned AU7000798A (en) 1996-11-05 1997-11-04 Pharmaceutical antigen-antibody preparation

Country Status (5)

Country Link
EP (1) EP0941118B1 (en)
AT (1) ATE204761T1 (en)
AU (1) AU7000798A (en)
DE (2) DE19645559A1 (en)
WO (1) WO1998019703A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8907271D0 (en) * 1989-03-31 1989-05-17 Univ Birmingham Method of preparing a vaccine
WO1991004750A1 (en) * 1989-10-02 1991-04-18 Embrex, Inc. Method of treatment
WO1994014976A1 (en) * 1992-12-18 1994-07-07 Duke University Immune response modulator complex, and uses thereof
DE19531226C1 (en) * 1995-08-24 1997-04-03 Immuno Ag Pharmaceutical compsn. for prevention or treatment of viral disease

Also Published As

Publication number Publication date
DE59704477D1 (en) 2001-10-04
WO1998019703A2 (en) 1998-05-14
EP0941118A2 (en) 1999-09-15
EP0941118B1 (en) 2001-08-29
WO1998019703A3 (en) 1998-08-06
DE19645559A1 (en) 1998-05-07
ATE204761T1 (en) 2001-09-15

Similar Documents

Publication Publication Date Title
AU2002355677A1 (en) Antigenic polypeptides
EP0955059A3 (en) Vaccines containing a saponin and a sterol
AU2843889A (en) Antigen antibody conjugate
EP1181938A3 (en) Rapamycin conjugates and antibodies
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
AU5055593A (en) Antibodies specific for HIV
CA2246715A1 (en) Antibody variants
AU5869596A (en) Anti-gp130 monoclonal antibodies
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
AU3407197A (en) Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
HUP9702359A3 (en) Monoclonal antibody, method of preparing a monoclonal antibody, and pharmaceutical composition and a diagnostic reagent comprising the monoclonal antibody
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
CA2193870A1 (en) Treponema Pallidum Fused Antigen and Assay for Anti-Treponema Pallidum Antibodies Using the Same Fused Antigen
AU7068587A (en) Monoclonal antibody immunoblot assay for antigens
AU6031090A (en) Monoclonal antibodies against a tumor-associated antigen
AU2696495A (en) Method for determining hiv-1 antigen and antibody
AU1423892A (en) Monoclonal antibodies directed towards mycobacterial antigens
AU1041397A (en) Antigenic protein originating in malassezia
AU3018289A (en) Anaplasma marginale antigen, antigen compositions, vaccine and process for the production of said antigen, antigen compositions, and vaccine
AU7000798A (en) Pharmaceutical antigen-antibody preparation
DE59608073D1 (en) ANTIBODIES AGAINST A FUSION POLYPEPTIDE HAVING A HISTIDINE PART
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
AU2484488A (en) Method for the production of antigenic protein-hapten conjugates, and antibodies corresponding thereto